Biogen secures robust deal with TJ Biopharma in massive $850 million China rights acquisition
In a revolutionary move, Biogen has struck a monumental deal for the China rights to an immune disease drug, partnering with TJ Biopharma. The agreement could reach a staggering $850.....
Subscribe for Full Access!
Gain valuable sourcing and trade intelligence from our database of millions of data points spanning 20+ years!
